ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 64 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,395,976 | -34.0% | 150,105 | -29.7% | 0.00% | – |
| Q1 2024 | $2,116,142 | +307.9% | 213,536 | +33.0% | 0.00% | – |
| Q4 2023 | $518,741 | -20.6% | 160,601 | +30.5% | 0.00% | – |
| Q3 2023 | $653,263 | -55.1% | 123,025 | -19.5% | 0.00% | – |
| Q2 2023 | $1,456,442 | +404.3% | 152,827 | +482.1% | 0.00% | – |
| Q1 2023 | $288,805 | -20.9% | 26,255 | +37.6% | 0.00% | – |
| Q3 2022 | $365,000 | +31.8% | 19,081 | +32.5% | 0.00% | – |
| Q1 2022 | $277,000 | -13.7% | 14,398 | +31.4% | 0.00% | – |
| Q3 2020 | $321,000 | – | 10,959 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $128,526,634 | 7.99% |
| Saturn V Capital Management LP | 487,179 | $8,787,113 | 7.29% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $44,400 | 4.96% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $8,421,807 | 3.66% |
| Logos Global Management LP | 1,400,000 | $20,720,000 | 2.43% |
| Rubric Capital Management LP | 2,742,519 | $40,589,281 | 1.77% |
| 1492 Capital Management LLC | 174,546 | $2,583,281 | 1.67% |
| AlphaCentric Advisors LLC | 78,500 | $1,161,800 | 1.15% |
| MPM BioImpact LLC | 262,069 | $3,878,621 | 1.01% |
| Orbimed Advisors | 2,460,108 | $36,409,598 | 0.70% |